Vitamin D bioavailability in cystic fibrosis: A cause for concern?

Nutrition Reviews

Volumn 70, Issue 5, 2012, Pages 280-293

  Mailhot, Geneviève ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Bioavailability; Cystic fibrosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; VITAMIN D;

ADAPTIVE IMMUNITY; ARTICLE; BIOAVAILABILITY; CYSTIC FIBROSIS; HUMAN; INNATE IMMUNITY; INTESTINE ABSORPTION; KIDNEY METABOLISM; LIVER METABOLISM; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PATHOLOGY; PHOTOBIOLOGY; PREGNANCY; STORAGE; TISSUE METABOLISM; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

BIOLOGICAL AVAILABILITY; CYSTIC FIBROSIS; HUMANS; INTESTINAL ABSORPTION; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84860344127     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2012.00471.x     Document Type: Article

References (127)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891-1904.
2. Rovner AJ, Stallings VA, Schall JI, etal. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr. 2007;86:1694-1699.
3. Neville LA, Ranganathan SC. Vitamin D in infants with cystic fibrosis diagnosed by newborn screening. J Paediatr Child Health. 2009;45:36-41.
4. Feranchak AP, Sontag MK, Wagener JS, etal. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr. 1999;135:601-610.
5. Ahn J, Yu K, Stolzenberg-Solomon R, etal. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19:2739-2745.
6. Wang TJ, Zhang F, Richards JB, etal. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180-188.
7. Ross AC, Manson JE, Abrams SA, etal. The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc. 2011;111:524-527.
8. Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011;26:455-457.
9. Chapuy MC, Preziosi P, Maamer M, etal. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-443.
10. Heaney RP, Dowell MS, Hale CA, etal. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142-146.
11. Tangpricha V, Kelly A, Stephenson A, etal. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012, Mar 7.
12. West NE, Lechtzin N, Merlo CA, etal. Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. Chest. 2011;140:469-474.
13. Sermet-Gaudelus I, Bianchi ML, Garabedian M, etal. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011;10(Suppl 2):S16-S23.
14. Solomons NW, Wagonfeld JB, Rieger C, etal. Some biochemical indices of nutrition in treated cystic fibrosis patients. Am J Clin Nutr. 1981;34:462-474.
15. Boyle MP, Noschese ML, Watts SL, etal. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:212-217.
16. Wolfenden LL, Judd SE, Shah R, etal. Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf). 2008;69:374-381.
17. Stephenson A, Brotherwood M, Robert R, etal. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007;85:1307-1311.
18. Boas SR, Hageman JR, Ho LT, etal. Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009;8:270-272.
19. Green D, Carson K, Leonard A, etal. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008;153:554-559.
20. Khazai NB, Judd SE, Jeng L, etal. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab. 2009;94:2037-2043.
21. Green DM, Leonard AR, Paranjape SM, et al. Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010;9:143-149.
22. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391.
23. Gibney EM, Goldfarb DS. The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis. 2003;42:1-11.
24. Sidhu H, Hoppe B, Hesse A, etal. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998;352:1026-1029.
25. Diffey BL. Is casual exposure to summer sunlight effective at maintaining adequate vitamin D status? Photodermatol Photoimmunol Photomed. 2010;26:172-176.
26. Jacob AI, Sallman A, Santiz Z, etal. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr. 1984;114:1313-1319.
27. Klein GL, Langman CB, Herndon DN. Vitamin D depletion following burn injury in children: a possible factor in post-burn osteopenia. J Trauma. 2002;52:346-350.
28. Matsuoka LY, Wortsman J, Haddad JG, etal. Cutaneous formation of vitamin D in psoriasis. Arch Dermatol. 1990;126:1107-1108.
29. Lepage G, Levy E, Ronco N, etal. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J Lipid Res. 1989;30:1483-1490.
30. Holick MF, Tian XQ, Allen M. Evolutionary importance for the membrane enhancement of the production of vitamin D3 in the skin of poikilothermic animals. Proc Natl Acad Sci U S A. 1995;92:3124-3126.
31. Sato F, Soos G, Link C, etal. Cystic fibrosis transport regulator and its mRNA are expressed in human epidermis. J Invest Dermatol. 2002;119:1224-1230.
32. McCarty CA. Sunlight exposure assessment: can we accurately assess vitamin D exposure from sunlight questionnaires? Am J Clin Nutr. 2008;87:S1097-S1101.
33. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 1995;39:793.
34. Cheng MP, Paquette K, Lands LC, etal. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients? Pediatr Pulmonol. 2010;45:661-666.
35. Gordon CM, Anderson EJ, Herlyn K, etal. Nutrient status of adults with cystic fibrosis. J Am Diet Assoc. 2007;107:2114-2119.
36. Grey V, Atkinson S, Drury D, etal. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics. 2008;122:1014-1020.
37. Reboul E, Goncalves A, Comera C, etal. Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol Nutr Food Res. 2011;55:691-702.
38. Mailhot G, Rabasa-Lhoret R, Moreau A, etal. CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells. PLoS ONE. 2010;doi:10.1371/journal.pone.0010446.
39. Canale-Zambrano JC, Poffenberger MC, Cory SM, etal. Intestinal phenotype of variable-weight cystic fibrosis knockout mice. Am J Physiol Gastrointest Liver Physiol. 2007;293:G222-G229.
40. Norkina O, Kaur S, Ziemer D, etal. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2004;286:G1032-G1041.
41. Mailhot G, Ravid Z, Barchi S, etal. CFTR knockdown stimulates lipid synthesis and transport in intestinal Caco-2/15 cells. Am J Physiol Gastrointest Liver Physiol. 2009;297:G1239-G1249.
42. Lark RK, Lester GE, Ontjes DA, etal. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr. 2001;73:602-606.
43. Lo CW, Paris PW, Clemens TL, etal. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985;42:644-649.
44. Soliman AT, Al Khalaf F, Alhemaidi N, etal. Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism. 2008;57:95-102.
45. Soliman AT, Adel A, Wagdy M, etal. Manifestations of severe vitamin D deficiency in adolescents: effects of intramuscular injection of a megadose of cholecalciferol. J Trop Pediatr. 2010;57:303-306.
46. Diamond TH, Ho KW, Rohl PG, etal. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust. 2005;183:10-12.
47. Ontjes DALR, Lester GE, Hollis BW, etal. Vitamin D depletion and replacement in patients with cystic fibrosis. In: Norman AWBR, Thomasset M, eds. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Riverside, CA: University of California, Printing and Reprographics; 2000:893-896.
48. Blum M, Dolnikowski G, Seyoum E, etal. Vitamin D(3) in fat tissue. Endocrine. 2008;33:90-94.
49. Heaney RP, Horst RL, Cullen DM, etal. Vitamin D3 distribution and status in the body. J Am Coll Nutr. 2009;28:252-256.
50. Coppenhaver D, Kueppers F, Schidlow D, etal. Serum concentrations of vitamin D-binding protein (group-specific component) in cystic fibrosis. Hum Genet. 1981;57:399-403.
51. Speeckaert MM, Wehlou C, Vandewalle S, etal. Vitamin D binding protein, a new nutritional marker in cystic fibrosis patients. Clin Chem Lab Med. 2008;46:365-370.
52. Zella LA, Shevde NK, Hollis BW, etal. Vitamin D-binding protein influences total circulating levels of 1, 25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology. 2008;149:3656-3667.
53. Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2009;25:272-278.
54. Plourde V, Gascon-Barre M, Coulombe PA, etal. Hepatic handling of vitamin D3 in micronodular cirrhosis: a structure-function study in the rat. J Bone Miner Res. 1988;3:461-471.
55. Plourde V, Gascon-Barre M, Willems B, etal. Severe cholestasis leads to vitamin D depletion without perturbing its C-25 hydroxylation in the dog. Hepatology. 1988;8:1577-1585.
56. Ziv E, Bar-On H, Silver J. Vitamin D3 uptake by the isolated perfused rat liver from lipoprotein fractions is separate from cholesterol and triglyceride uptake. Eur J Clin Invest. 1985;15:95-99.
57. Gascon-Barre M, Huet PM, St-Onge-Brault G, etal. Liver extraction of vitamin D3 is independent of its hepatic venous or arterial route of delivery. Studies in isolated-perfused rat liver preparations. J Pharmacol Exp Ther. 1988;245:975-981.
58. Levy E, Lepage G, Bendayan M, etal. Relationship of decreased hepatic lipase activity and lipoprotein abnormalities to essential fatty acid deficiency in cystic fibrosis patients. J Lipid Res. 1989;30:1197-1209.
59. Kinnman N, Lindblad A, Housset C, etal. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology. 2000;32:334-340.
60. Cheng JB, Levine MA, Bell NH, etal. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101:7711-7715.
61. Velsor LW, Kariya C, Kachadourian R, etal. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol. 2006;35:579-586.
62. Velsor LW, van Heeckeren A, Day BJ. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol. 2001;281:L31-L38.
63. Antigny F, Norez C, Becq F, etal. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium. 2008;43:175-183.
64. Kelly M, Trudel S, Brouillard F, etal. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J Pharmacol Exp Ther. 2010;333:60-69.
65. Shapiro BL. Evidence for a mitochondrial lesion in cystic fibrosis. Life Sci. 1989;44:1327-1334.
66. Li C, Naren AP. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol Ther. 2005;108:208-223.
67. Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens. 2009;18:298-302.
68. McKibbin CRDL, Clines KL, Clines GA. Mechanisms of reduced osteoblast activity and enhanced osteoclastogenesis in CF bone disease. In: Program and abstracts of the 23rd Annual North American Cystic Fibrosis Conference; October 15-17, 2009; Minneapolis, Minn. p. 416.
69. Theodoropoulos C, Demers C, Delvin E, etal. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol (Oxf). 2003;58:489-499.
70. Theodoropoulos C, Demers C, Mirshahi A, etal. 1, 25-Dihydroxyvitamin D(3) downregulates the rat intestinal vitamin D(3)-25-hydroxylase CYP27A. Am J Physiol Endocrinol Metab. 2001;281:E315-E325.
71. Adams JS, Sharma OP, Gacad MA, etal. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983;72:1856-1860.
72. Dusso AS, Finch J, Brown A, etal. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72:157-164.
73. Abreu MT, Kantorovich V, Vasiliauskas EA, etal. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1, 25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53:1129-1136.
74. Werlin SL, Benuri-Silbiger I, Kerem E, etal. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010;51:304-308.
75. Nykjaer A, Dragun D, Walther D, etal. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999;96:507-515.
76. Anderson RL, Ternes SB, Strand KA, etal. Vitamin D homeostasis is perturbed due to urinary excretion of the 25-hydroxycholecalciferol-vitamin D-binding protein complex in the Zucker diabetic fatty rat. Am J Physiol Endocrinol Metab. 2010;299:E959-E967.
77. Nykjaer A, Fyfe JC, Kozyraki R, etal. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A. 2001;98:13895-13900.
78. Jouret F, Bernard A, Hermans C, etal. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol. 2007;18:707-718.
79. Aris RM, Lester GE, Dingman S, etal. Altered calcium homeostasis in adults with cystic fibrosis. Osteoporos Int. 1999;10:102-108.
80. Brown SA, Ontjes DA, Lester GE, etal. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. Osteoporos Int. 2003;14:442-449.
81. Hillman LS, Cassidy JT, Popescu MF, etal. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: effect of supplementation with vitamin D and calcium. Pediatr Pulmonol. 2008;43:772-780.
82. Wang TT, Nestel FP, Bourdeau V, etal. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173:2909-2912.
83. Yim S, Dhawan P, Ragunath C, etal. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1, 25-dihydroxyvitamin D(3). J Cyst Fibros. 2007;6:403-410.
84. Pincikova T, Nilsson K, Moen IE, etal. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr. 2011;65:102-109.
85. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest. 2005;128:3792-3798.
86. Chavasse RJ, Francis J, Balfour-Lynn I, etal. Serum vitamin D levels in children with cystic fibrosis. Pediatr Pulmonol. 2004;38:119-122.
87. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, etal. Low bone mineral density in young children with cystic fibrosis. Am J Respir Crit Care Med. 2007;175:951-957.
88. Zosky GR, Berry LJ, Elliot JG, etal. Vitamin D deficiency causes deficits in lung function and alters lung structure. Am J Respir Crit Care Med. 2011;183:1336-1343.
89. Bitetto D, Fabris C, Falleti E, etal. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int. 2010;30:417-444.
90. Lowery E, Landmeier MW, etal. Effect of serum vitamin D 25(OH) levels on outcome in patients with cystic fibrosis undergoing lung transplantation. Am J Resp Crit Care Med. 2010;181:A4324.
91. Smith JJ, Travis SM, Greenberg EP, etal. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85:229-236.
92. Liu PT, Stenger S, Li H, etal. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770-1773.
93. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164:2405-2411.
94. Penna G, Amuchastegui S, Giarratana N, etal. 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol. 2007;178:145-153.
95. Peelen E, Knippenberg S, Muris AH, etal. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011;10:733-743.
96. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010;39:365-379.
97. Morales-Tirado V, Wichlan DG, Leimig TE, etal. 1alpha, 25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3. Clin Immunol. 2011;138:212-221.
98. Jeffery LE, Burke F, Mura M, etal. 1, 25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183:5458-5467.
99. Kreindler JL, Steele C, Nguyen N, etal. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 2010;120:3242-3254.
100. Ikeda U, Wakita D, Ohkuri T, etal. 1alpha, 25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett. 2010;134:7-16.
101. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res. 2007;56:221-227.
102. Brodlie M, McKean MC, Johnson GE, etal. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J. 2011;37:1378-1385.
103. Decraene A, Willems-Widyastuti A, Kasran A, etal. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res. 2010;11:177.
104. Chen S, Sims GP, Chen XX, etal. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179:1634-1647.
105. Levy H, Kalish LA, Huntington I, etal. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol. 2007;42:256-262.
106. Wheeler WB, Williams M, Matthews WJ Jr, etal. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr. 1984;104:695-699.
107. Norman AW, Frankel JB, Heldt AM, etal. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823-825.
108. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest. 1984;73:759-766.
109. Chamnan P, Shine BS, Haworth CS, etal. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33:311-316.
110. Cross HS, Peterlik M, Reddy GS, etal. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol. 1997;62:21-28.
111. Tong WM, Hofer H, Ellinger A, etal. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol Res. 1999;11:77-84.
112. Lechner D, Kallay E, Cross HS. 1alpha, 25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells. Mol Cell Endocrinol. 2007;263:55-64.
113. Maisonneuve P, FitzSimmons SC, Neglia JP, etal. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95:381-387.
114. Neglia JP, FitzSimmons SC, Maisonneuve P, etal. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332:494-499.
115. Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, etal. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev. 2009;10:134-142.
116. van Driel M, Koedam M, Buurman CJ, etal. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J. 2006;20:2417-2419.
117. Kogawa M, Findlay DM, Anderson PH, etal. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology. 2010;151:4613-4625.
118. Shead EF, Haworth CS, Condliffe AM, etal. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax. 2007;62:650-651.
119. Cystic Fibrosis Foundation. Patient Registry: Annual Data Report 2009. Bethesda, MD: Cystic Fibrosis Foundation; 2011.
120. Bodnar LM, Catov JM, Simhan HN, etal. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab. 2007;92:3517-3522.
121. Bodnar LM, Catov JM, Zmuda JM, etal. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr. 2010;140:999-1006.
122. Weiler H, Fitzpatrick-Wong S, Veitch R, etal. Vitamin D deficiency and whole-body and femur bone mass relative to weight in healthy newborns. CMAJ. 2005;172:757-761.
123. Lapillonne A. Vitamin D deficiency during pregnancy may impair maternal and fetal outcomes. Med Hypotheses. 2010;74:71-75.
124. Feron F, Burne TH, Brown J, etal. Developmental vitamin D3 deficiency alters the adult rat brain. Brain Res Bull. 2005;65:141-148.
125. Walker VP, Zhang X, Rastegar I, etal. Cord blood vitamin D status impacts innate immune responses. J Clin Endocrinol Metab. 2011;96:1835-1843.
126. Doorenbos CR, van den Born J, Navis G, etal. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol. 2009;5:691-700.
127. White JH. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. J Steroid Biochem Mol Biol. 2010;121:234-238.